Angiogenesis in non-Hodgkin's lymphoma: Clinico-pathological correlations and prognostic significance in specific subtypes

被引:59
作者
Jorgensen, J. M.
Sorensen, F. B.
Bendix, K.
Nielsen, J. L.
Olsen, M. L.
Funder, A. M. D.
D'Amore, F.
机构
[1] Aarhus Univ Hosp, Dept Pathol, DK-8000 Aarhus, Denmark
[2] Aarhus Univ Hosp, Dept Haematol, DK-8000 Aarhus, Denmark
[3] Aarhus Univ, Dept Clin Epidemiol, Aarhus, Denmark
关键词
angiogenesis; Chalkley method; microvessel density method (MVD); non-Hodgkin's lymphoma (NHL); prognosis;
D O I
10.1080/10428190601083241
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of the study was to evaluate angiogenesis in different subtypes of non-Hodgkin's lymphoma (NHL) and to correlate angiogenic scores to clinical endpoints. Pre-therapeutic lymph node biopsies from 308 patients with NHL [107 follicular B-cell lymphoma (FL), 94 diffuse large B-cell lymphoma (DLBCL), 107 peripheral T-cell lymphoma (PTCL)] were studied. Microvessels were scored according to the Chalkley and microvessel density method (MVD) methods. Vascular endothelial growth factor (VEGF) protein expression was evaluated by immunohistochemistry. Both Chalkley and MVD methods showed, that the lymphoma subtypes differed significantly in angiogenic scores (P < 0.001). Angiogenic scores in tumor area were highest in PTCL, and lowest in FL. However, a remarkable high microvessel density was found in interfollicular areas of FL. In FL, high interfollicular MVD scores predicted progressive disease and poorer overall and event-free survival (P=0.024 and 0.013). High interfollicular Chalkley scores correlated with transformation to DLBCL (P=0.01). VEGF expression was detected in all NHL subtype, and the strongest expression was found in PTCL. In FL, patients with diffuse VEGF expression in lymphoma cells had poorer overall survival than those with focal expression.
引用
收藏
页码:584 / 595
页数:12
相关论文
共 65 条
  • [1] Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)
    Achen, MG
    Jeltsch, M
    Kukk, E
    Mäkinen, T
    Vitali, A
    Wilks, AF
    Alitalo, K
    Stacker, SA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) : 548 - 553
  • [2] Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
    Aguayo, A
    Kantarjian, H
    Manshouri, T
    Gidel, C
    Estey, E
    Thomas, D
    Koller, C
    Estrov, Z
    O'Brien, S
    Keating, M
    Freireich, E
    Albitar, M
    [J]. BLOOD, 2000, 96 (06) : 2240 - 2245
  • [3] Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival
    Andersen, NF
    Standal, T
    Nielsen, JL
    Heickendorff, L
    Borset, M
    Sorensen, FB
    Abildgaard, N
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (02) : 210 - 217
  • [4] Predictive capacity of the international prognostic factor index in patients with peripheral T-cell lymphoma
    Ansell, SM
    Habermann, TM
    Kurtin, PJ
    Witzig, TE
    Chen, MG
    Li, CY
    Inwards, DJ
    Colgan, JP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) : 2296 - 2301
  • [5] The interplay between c-Myc oncogene expression and circulating vascular endothelial growth factor (sVEGF), its antagonist receptor, soluble Flt-1 in diffuse large B cell lymphoma (DLBCL): Relationship to patient outcome
    Aref, S
    Mabed, M
    Zalata, K
    Sakrana, M
    El Askalany, H
    [J]. LEUKEMIA & LYMPHOMA, 2004, 45 (03) : 499 - 506
  • [6] Arias V, 2000, LEUKEMIA LYMPHOMA, V40, P157
  • [7] Microvessel density in chemosensitive and chemoresistant diffuse large B-cell lymphomas
    Bairey, O
    Zimra, Y
    Kaganovsky, E
    Shaklai, M
    Okon, E
    Rabizadeh, E
    [J]. MEDICAL ONCOLOGY, 2000, 17 (04) : 314 - 318
  • [8] Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients
    Bastion, Y
    Sebban, C
    Berger, F
    Felman, P
    Salles, G
    Dumontet, C
    Bryon, PA
    Coiffier, B
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (04) : 1587 - 1594
  • [9] Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma
    Bertolini, F
    Paolucci, M
    Peccatori, F
    Cinieri, S
    Agazzi, A
    Ferrucci, PF
    Cocorocchio, E
    Goldhirsch, A
    Martinelli, G
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (02) : 504 - 509
  • [10] Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma
    Bono, P
    Teerenhovi, L
    Joensuu, H
    [J]. CANCER, 2003, 97 (11) : 2767 - 2775